Mario Amendola, PhD CR1
UMR_951 Integrated Genetic Approaches in Therapeutic Discovery for Rare Diseases
Tel.: +33 (0)1 69 47 10 24
Researchers have developed a tool to modify the genome of stem cells and restore the production of therapeutic proteins in patients. © Adobe Stock
Finding appropriate treatments for patients with hereditary diseases, such as hemophilia and most metabolic disorders, is often a challenge for researchers. Targeted genome editing, particularly via the CRISPR-Cas9 technique, has opened up some interesting avenues in recent years. Researchers from Inserm, Université d’Evry, Université Paris-Saclay and Genethon have developed a novel platform for modifying the genome of hematopoietic stem cells, which give rise to blood cells. The use of these tools could provide new therapeutic solutions for many patients with rare genetic diseases. The results of this research have been published in Nature Communications.
Various hereditary diseases, such as hemophilia or most metabolic disorders, are characterized by the absence of certain proteins in the body. Hemophilia in particular is caused by a clotting factor deficiency. In the event of injury, the blood does not clot properly, resulting in severe bleeding in some cases. In metabolic disorders, the cause is a metabolic enzyme deficiency that impedes the degradation of certain substrates, leading to vital organ failure and even death.
Although substitution treatments exist, they can be burdensome for patients and particularly costly. What is more, because they involve bringing foreign proteins into the body, these treatments can be neutralized by the immune system.
To explore new therapeutic solutions, a team from the Integrated Genetic Approaches in Therapeutic Discovery for Rare Diseases laboratory (Inserm/Université d’Evry/Université Paris-Saclay) led by Mario Amendola, an Inserm researcher at Genethon, has focused on two rare hereditary diseases: hemophilia B and a metabolic condition called Wolman disease.
The first concerns around one in 25,000 boys and is caused by a deficiency of a clotting protein called factor IX. The second affects one in 100,000 births and is caused by a lysosomal acid lipase (LAL) deficiency.
The researchers have developed a novel genome-editing platform aimed at restoring the secretion of these proteins. Described for the first time in the journal Nature Communications, this unique tool is based on the editing of the hematopoietic stem cell genome. Hematopoietic stem cells give rise to the various blood cell types, differentiating in particular to form red blood cells.
To achieve this result, the researchers first identified and characterized a region of the hematopoietic stem cell genome that could be safely modified. Using “CRISPR-Case 9” genetic scissors, they inserted isolated DNA sequences into it so that only the red blood cells derived from it could then systematically express a large amount of factor IX or LAL.
“This study aims to describe for the first time a technique for modifying the genome of hematopoietic stem cells. This is so that red blood cells, which are very abundant in the body, then secrete beneficial therapeutic proteins – without risk to patients and without rejection by the immune system, since they are produced by their cells,” clarifies Amendola.
This research therefore opens up interesting therapeutic avenues for many patients, requiring testing of the platform in a clinical setting. “The technology is promising and applicable to many diseases, but to make it a therapeutic solution in its own right, it is essential to continue this fundamental work in order to bring it to the hospital, to the patients,” concludes Amendola.
Pourquoi la réponse individuelle à l'infection par le virus SARS-CoV2 varie-t-elle autant d’une personne à l’autre ? Résoudre ce mystère permettrait d’identifier les patients à risque, d’anticiper et d’améliorer leur prise en charge et d’offrir de nouvelles voies thérapeutiques fondées sur une meilleure ...
Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
Giulia Pavani1-2, Marine Laurent1-2, Anna Fabiano1-2, Erika Cantelli1-2, Aboud Sakkal1-2, Guillaume Corre1-2, Peter J. Lenting3, Jean-Paul Concordet4, Magali Toueille1, Annarita Miccio5, Mario Amendola1-2*
1 Genethon, 91000, Evry, France
2 Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare research unit UMR_S951, 91000, Evry, France
3 Laboratory of Hemostasis-Inflammation-Thrombosis, UMR_S1176, Inserm, Univ. Paris-Sud, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France.
4 National Museum of Natural History, UMR_1154 Inserm, UMR_7196 CNRS, Univ Sorbonne, Paris, France.
5 Université de Paris, Imagine Institute, Laboratory of chromatin and gene regulation during development, INSERM UMR 1163, F-75015, Paris, France
*Corresponding author: firstname.lastname@example.org
Nature Communications, juillet 2020